Xin T Su

US Patent:

7205114, Apr 17, 2007

Filed:

May 13, 2004

Appl. No.:

10/846380

Inventors:

Harry Prince - Los Angeles CA, US
Xin Su - Irvine CA, US
Lilly Kong - Covina CA, US
Celine Ngo, legal representative - Garden Grove CA, US
Sergei Arakelov - Santa Monica CA, US
Wayne Hogrefe - Lake Forest CA, US

Assignee:

Focus Technologies, Inc. - Cypress CA

International Classification:

G01N 33/53

US Classification:

435 71

Abstract:

The present invention relates to oxidized fungal antigens and methods of making and using thereof. More particularly, the present invention provides a method for producing an oxidized fungal antigen in culture filtrate. The present invention also provides for the produced oxidized fungal antigens. Devices comprising such oxidized fungal antigens, methods for testing for fungal antibodies using the oxidized fungal antigens and methods for producing anti-fungal antibodies using oxidized fungal antigens are further provided. Antigen detection devices comprising anti-fungal antibodies raised against oxidized fungal antigens produced by the present methods are further provided.

US Patent:

7763460, Jul 27, 2010

Filed:

Dec 6, 2005

Appl. No.:

11/296571

Inventors:

Xin Su - Irvine CA, US
Lilly Kong - Covina CA, US
Wayne Hogrefe - Cypress CA, US

Assignee:

Focus Diagnostics, Inc. - Herndon VA

International Classification:

C12N 5/06

US Classification:

435345, 435 5

Abstract:

The invention provides methods for sensitive and specific detection of anti-HSV-2 antibodies by depletion of cross-reactive (non-specific) antibodies in a biological sample that can lead to a false positive result. The invention also features compositions, including nucleic acids, polypeptides, and kits, for use in the methods of the invention.

US Patent:

20030039957, Feb 27, 2003

Filed:

Nov 27, 2001

Appl. No.:

09/996187

Inventors:

Laurence McCarthy - Great Falls VA, US
Lilly Kong - Covina CA, US
Tang Shao - Rosemead CA, US
Xin Su - Irvine CA, US

International Classification:

C12Q001/70
C12Q001/68
G01N033/53
G01N033/554
G01N033/569

US Classification:

435/005000, 435/006000, 435/007100, 435/007320

Abstract:

Disclosed herein are methods for assaying the phenotype of a bioactive molecule in the presence and absence of compounds that are known inhibitors of the phenotypable activity of the bioactive molecule. Also disclosed are methods for discovering compounds that can inhibit the phenotypable activity of a bioactive molecule. The methods and assays of the present invention are useful in developing and monitoring a chemotherapy regimen for a patient, to detect or prevent the emergence of a drug resistant phenotype.

US Patent:

20030124630, Jul 3, 2003

Filed:

Dec 21, 2001

Appl. No.:

10/028181

Inventors:

Harry Prince - Los Angeles CA, US
Xin Su - Irvine CA, US
Lilly Kong - Covina CA, US
Ken Devor - Cypress CA, US
Sergei Arakelov - Los Angeles CA, US
Wayne Hogrefe - Lake Forest CA, US

International Classification:

G01N033/53
G01N033/569
G01N033/554

US Classification:

435/007320

Abstract:

The present invention relates to oxidized fungal antigens and methods of making and using thereof. More particularly, the present invention provides a method for producing an oxidized fungal antigen in culture filtrate. The present invention also provides for the produced oxidized fungal antigens. Devices comprising such oxidized fungal antigens, methods for testing for fungal antibodies using the oxidized fungal antigens and methods for producing anti-fungal antibodies using oxidized fungal antigens are further provided. Antigen detection devices comprising anti-fungal antibodies raised against oxidized fungal antigens produced by the present methods are further provided.

US Patent:

20060057643, Mar 16, 2006

Filed:

Sep 9, 2005

Appl. No.:

11/223785

Inventors:

Laurence McCarthy - Great Falls VA, US
Lilly Kong - Covina CA, US
Xin Su - Irvine CA, US
Tang Shao - Rosemead CA, US

International Classification:

C12Q 1/68
G01N 33/53

US Classification:

435007100, 435006000

Abstract:

The invention provides methods and compositions for rapid, sensitive, and highly specific nucleic acid-based (e.g., DNA based) detection of human erythroviruses, such as the B19, V9, and A6 genotype, in a sample. In general, the methods involve detecting a target nucleic acid having a target sequence of a conserved region of the erythrovirus genomes. The invention also features compositions, including primers, probes, and kits, for use in the methods of the invention.

US Patent:

20110059553, Mar 10, 2011

Filed:

Jun 23, 2010

Appl. No.:

12/822104

Inventors:

Xin Su - Irvine CA, US
Lilly Kong - Covina CA, US
Wayne Hogrefe - Lake Forest CA, US

International Classification:

G01N 33/566

US Classification:

436501

Abstract:

The invention provides methods for sensitive and specific detection of anti-HSV-2 antibodies by depletion of cross-reactive (non-specific) antibodies in a biological sample that can lead to a false positive result. The invention also features compositions, including nucleic acids, polypeptides, and kits, for use in the methods of the invention.

US Patent:

20160303376, Oct 20, 2016

Filed:

Apr 13, 2016

Appl. No.:

15/097990

Inventors:

- Minneapolis MN, US
Peng Cong - Cupertino CA, US
Xin Su - Plymouth MN, US

International Classification:

A61N 1/36
A61N 1/05

Abstract:

This disclosure relates to methods, devices, and systems for delivering and adjusting stimulation therapy. In one example, a system may include a stimulation generator configured to delivery electrical stimulation therapy to tissue of a patient in accordance with a stimulation therapy program. The stimulation therapy program may include a set of stimulation therapy parameters. The system may include at least one sensor configured to detect a signal including an evoked compound muscle action potential (eCMAP) in response to the application of stimulation according to the stimulation therapy program. The system may also include a processor configured to adjust one or more or the stimulation therapy parameters based on the detected signal that includes the eCMAP.